MCID: CTR002
MIFTS: 60

Cataract

Categories: Eye diseases, Fetal diseases, Genetic diseases, Metabolic diseases, Nephrological diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Cataract

Summaries for Cataract

KEGG : 36 Cataracts can be defined as any opacity of the crystalline lens, often associated with breakdown of the lens microarchitecture, possibly including vacuole formation and disarray of lens cells, which can cause large fluctuations in density resulting in light scattering. In addition, light scattering and opacity will occur if there is a significant amount of high molecular weight protein aggregates. Cataracts can be classified by the age at onset: a congenital or infantile cataract presents within the first year of life; a juvenile cataract presents within the first decade of life; a presenile cataract presents before the age of about 45 years, and senile or age-related cataract after that. Congenital cataracts are a major cause of induced blindness in children, and inherited cataracts are the major cause of congenital cataracts. Inherited congenital cataracts have been associated with mutations in specific genes, including those of crystallins, gap junction proteins, membrane transport and channel proteins, the cytoskeleton, and growth and transcription factors. Inherited congenital cataracts may be inherited as autosomal dominant (most frequent), autosomal recessive, or X-linked traits.

MalaCards based summary : Cataract, also known as cataracts, is related to cataract 1, multiple types and cataract 9, multiple types. An important gene associated with Cataract is LIM2 (Lens Intrinsic Membrane Protein 2), and among its related pathways/superpathways is Protein processing in endoplasmic reticulum. The drugs Tropicamide and Bimatoprost have been mentioned in the context of this disorder. Affiliated tissues include Eye, endothelial and testes, and related phenotype is vision/eye.

Disease Ontology : 12 A lens disease characterized by clouding of the lens inside the eye which leads to a decrease in vision.

MedlinePlus : 42 A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision Frequent prescription changes in your eye wear Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute

PubMed Health : 62 About cataracts: A cataract is an eye condition in which the lens of the eye becomes cloudy. This causes vision to worsen, making it especially difficult to see fine details clearly. Some people’s vision is only slightly affected, whereas others might lose their eyesight very quickly. How it progresses will depend on things like the exact type of cataract. The word “cataract” comes from the Greek word for “waterfall” because in the past it was believed that the blurring was caused by a fluid in the eye. Cataracts mostly affect people over 50, and the risk increases with age: About 20 out of 100 people between the ages of 65 and 74 have a cataract. And more than 50 out of 100 people over the age of 74 are affected. Cataracts are the main cause of blindness in developing countries. The number of people who go blind from cataracts is considerably lower in industrialized countries due to the availability of effective surgery. Cataract surgery involves removing the cloudy eye lens and replacing it with an artificial lens. It is one of the most common surgical procedures performed in Germany, where about 800,000 people have cataract surgery every year.

Wikipedia : 74 A cataract is an opacification of the lens of the eye which leads to a decrease in vision. Cataracts... more...

Related Diseases for Cataract

Diseases in the Cataract family:

Cataract 32, Multiple Types Cataract 7
Cataract 8, Multiple Types Cataract 4, Multiple Types
Cataract 29 Cataract 42
Cataract 20, Multiple Types Cataract 1, Multiple Types
Cataract 30, Multiple Types Cataract 41
Cataract 6, Multiple Types Cataract 5, Multiple Types
Cataract 40 Cataract 10, Multiple Types
Cataract 24 Cataract 3, Multiple Types
Cataract 14, Multiple Types Cataract 9, Multiple Types
Cataract 2, Multiple Types Cataract 31, Multiple Types
Cataract 25 Cataract 26, Multiple Types
Cataract 27 Cataract 28
Cataract 35 Cataract 22, Multiple Types
Cataract 18 Cataract 21, Multiple Types
Cataract 23, Multiple Types Cataract 11, Multiple Types
Cataract 33, Multiple Types Cataract 17, Multiple Types
Cataract 12, Multiple Types Cataract 47
Cataract 34, Multiple Types Cataract 16, Multiple Types
Cataract 36 Cataract 37
Cataract 38 Cataract 39, Multiple Types
Cataract 15, Multiple Types Cataract 19, Multiple Types
Cataract 43 Cataract 44
Cataract 45 Cataract 48
Cataract 30 Cataract 33
Cataract Congenital Autosomal Dominant Cataract, Total Congenital

Diseases related to Cataract via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1654)
# Related Disease Score Top Affiliating Genes
1 cataract 1, multiple types 35.5 GJA8 GJA3 CRYAA
2 cataract 9, multiple types 35.3 GJA8 CRYAA
3 cataract 24 35.3 CTAA2 CRYBB3 CRYAA
4 cataract 16, multiple types 35.2 CRYBA1 CRYAA
5 cataract 6, multiple types 35.2 CRYBA1 CRYAA
6 cataract 44 35.2 LIM2 GJA8 CRYAA
7 cataract 30, multiple types 35.2 GJA8 GJA3 CRYGD
8 cataract 11, multiple types 35.2 CRYBA1 CRYAA
9 posterior polar cataract 35.2 GJA3 CRYGS CRYGD CRYBA1 CRYAA
10 cataract 32, multiple types 35.1 CRYBA1 CRYAA
11 cataract microcornea syndrome 35.1 GJA8 CRYGD CRYAA
12 cataract 14, multiple types 35.1 GJA8 GJA3
13 cataract 28 35.1 LIM2 CTRCT28 CRYAA
14 cataract 31, multiple types 35.1 CRYBA1 CRYAA
15 cerulean cataract 35.0 CTRCT37 CRYGD
16 cataract 29 35.0 CTRCT29 CRYGD
17 mature cataract 35.0 CRYGS CRYGD CRYAA
18 early-onset nuclear cataract 34.9 GJA8 GJA3 CRYGD CRYBB3 CRYBA1 CRYAA
19 morgagni cataract 34.8 CRYGS CRYAA
20 galactosemia ii 34.7 LIM2 CRYGS CRYBB3 CRYAA
21 diabetic cataract 34.6 CRYGS CRYAA
22 early-onset sutural cataract 34.6 GJA8 CRYGS CRYBA1
23 early-onset posterior polar cataract 34.5 GJA3 CRYBA1
24 nance-horan syndrome 34.5 CRYBB3 CRYBA1 CRYAA
25 early-onset lamellar cataract 34.4 CRYGS CRYGD CRYBA1 CRYAA
26 amblyopia 33.6 GJA3 CRYGS CRYBB3 CRYAA
27 hallermann-streiff syndrome 33.3 GJA3 CRYAA
28 marinesco-sjogren syndrome 33.2 SIL1 CRYAA
29 rare disorder with lens opacification 33.2 SIL1 RHO LIM2 IARS2
30 macular retinal edema 33.1 RHO CRYAA
31 lens disease 32.7 GJA8 GJA3 CRYGS CRYGD CRYBA1 CRYAA
32 leber congenital amaurosis 2 32.2 RHO CRYAA
33 pathologic nystagmus 32.1 RHO CRYBA1 CRYAA
34 presbyopia 31.7 CRYGS CRYAA
35 leukocoria 31.3 CRYBA1 CRYAA
36 disuse amblyopia 31.1 CRYGS CRYAA
37 sclerocornea 30.9 GJA8 CRYAA
38 vitreous disease 30.6 RHO CRYAA
39 hereditary retinal dystrophy 30.5 RHO CRYAA
40 congenital nystagmus 30.4 GJA8 CRYAA
41 hyperferritinemia with or without cataract 12.7
42 cataract 4, multiple types 12.7
43 cataract 21, multiple types 12.7
44 cataract 3, multiple types 12.6
45 cataract 17, multiple types 12.6
46 cataract 40 12.6
47 cataract 22, multiple types 12.6
48 cataract 2, multiple types 12.6
49 cataract 5, multiple types 12.6
50 cataract 10, multiple types 12.6

Graphical network of the top 20 diseases related to Cataract:



Diseases related to Cataract

Symptoms & Phenotypes for Cataract

MGI Mouse Phenotypes related to Cataract:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.23 CRYBA1 CRYGD CRYGS GJA3 GJA8 IARS2

Drugs & Therapeutics for Cataract

PubMed Health treatment related to Cataract: 62

Some people can compensate for the vision loss, temporarily or even in the longer term, by wearing glasses or contact lenses . There are no medications for the treatment of cataracts . The only effective treatment is surgery . Cataract surgery involves removing the cloudy lens and replacing it with a new, artificial lens. The lens capsule – an elastic membrane surrounding the lens of the eye – is left in the eye during surgery. Only the inner core and the outer cortex of the lens are broken up into small pieces using ultrasound. The pieces are then sucked out of the eye through a small cut. This procedure, called phacoemulsification , is the standard technique in Germany and some other countries. Once the lens has been removed, an artificial lens is implanted into the lens capsule. Whether and when surgery is an appropriate treatment option is very much a personal decision. The extent to which vision loss is affecting someone’s life will play a very important role. Another factor to consider is the presence of other (eye ) conditions, which could affect the outcome of cataract surgery .

Drugs for Cataract (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 428)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tropicamide Approved, Investigational Phase 4 1508-75-4 5593
2
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
3
Timolol Approved Phase 4 26839-75-8 5478 33624
4
Travoprost Approved Phase 4 157283-68-6 5282226
5
Dorzolamide Approved Phase 4 120279-96-1 5284549 3154
6
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
7
Cefazolin Approved Phase 4 25953-19-9 656510 33255
8
Promethazine Approved, Investigational Phase 4 60-87-7 4927
9
Abatacept Approved Phase 4 332348-12-6 10237
10
Acetaminophen Approved Phase 4 103-90-2 1983
11
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
12
Alogliptin Approved Phase 4 850649-61-5 11450633
13
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
14
Besifloxacin Approved Phase 4 141388-76-3
15
Dinoprostone Approved Phase 4 363-24-6 5280360
16
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
17
Difluprednate Approved Phase 4 23674-86-4 443936
18
Povidone Approved Phase 4 9003-39-8
19
Bromfenac Approved Phase 4 91714-94-2 60726
20
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
21
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
22
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
23
Polyestradiol phosphate Approved Phase 4 28014-46-2
24
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
25
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
26
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
27
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
28
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
29
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 9865442 444025
30
Enoxaparin Approved Phase 4 9005-49-6 772
31
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
32
Dalteparin Approved Phase 4 9005-49-6
33 Orange Approved Phase 4
34
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
35
Azithromycin Approved Phase 4 83905-01-5 447043 55185
36
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
37
Homatropine Approved Phase 4 87-00-3
38
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
39
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
40
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
41
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
42
Ethanol Approved Phase 4 64-17-5 702
43
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
44
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
45
Budesonide Approved Phase 4 51333-22-3 63006 5281004
46
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
47
Mycophenolic acid Approved Phase 4 24280-93-1 446541
48
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
49
Triazolam Approved, Investigational Phase 4 28911-01-5 5556
50
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946

Interventional clinical trials:

(show top 50) (show all 1607)
# Name Status NCT ID Phase Drugs
1 Relevance of Eye Dominance in the Selection of Patients Suitable for Treatment With Monovision After Cataract Surgery Unknown status NCT01382641 Phase 4
2 Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia Unknown status NCT01554761 Phase 4
3 A Study to Assess the Clinical Outcomes of Surgical Phaco Segmentation Techniques in Patients Undergoing Cataract Surgery Unknown status NCT02843594 Phase 4
4 Clinical Investigation of the Modified Rayner Monofocal Aspheric 600C (With Axis Marks) Intraocular Lens Unknown status NCT02378636 Phase 4
5 Efficacy of Subtenon Anesthesia With Olive Tipped Cannula: a Randomized Controlled Trial Unknown status NCT01019018 Phase 4
6 AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL Unknown status NCT01278420 Phase 4
7 Comparative Study of the Safety and Effectiveness Between Off-Label Subconjunctival Bevacizumab and Mitomycin C in Glaucoma Filtering Surgery. Unknown status NCT00468429 Phase 4 Subconjunctival Bevacizumab
8 Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Unknown status NCT01193504 Phase 4 Pred Forte;Lotemax
9 The Effect of Pretreated Gabapentin on Hyeralgesia Occurring in the Second Operation in Staged Bilateral Cataract Surgery Unknown status NCT02127853 Phase 4 gabapentin;placebo
10 Clinical Evaluation of Toric Intraocular Lens Made by Aurolab Unknown status NCT01396616 Phase 4
11 Quantitative Comparison of the Efficacy of Subtenon 20-mg Triamcinolone Injection With 0.1% Dexamethasone Eye Drop in Controlling Intraocular Inflammation After Phacoemulsification Unknown status NCT01801774 Phase 4 Subtenon 20-mg triamcinolone injection;Placebo
12 Effect of Anti-inflammatory Topical Prednisolone Acetate 1%, Nepafenac of 0.1% and Ketorolac Tromethamine 0.4% in Intra-operative Mydriasis in Facetectomies Unknown status NCT00865540 Phase 4 prednisolone acetate 1%;ketorolac tromethamine 0.4%;nepafenac 0.1%;methylcellulose 0.5%
13 Combined Phacoemulsification and Glaucoma Implant Surgery Versus Combined Phacoemulsification and Trabeculectomy: A Randomized Controlled Trial Unknown status NCT00273221 Phase 4
14 Assessment in Early Changes in the Parameters of Optical Coherence Tomography (OCT Spectral Domain) in Patients With Subfoveal Neovascular Membranes Related to Age After Treatment With a Single Intravitreal Injection of Lucentis. Unknown status NCT01669447 Phase 4
15 Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves Unknown status NCT01535768 Phase 4 Aqueous Suppressant Eye Drops
16 Heavy Bupivacaine Versus Plain Bupivacaine in Peribulbar Block Unknown status NCT03312959 Phase 4 hyperbaric bupvacaine in Peribulbar block;isobaric bupvacaine in Peribulbar block
17 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
18 A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperative Topical Prostaglandin Unknown status NCT02873806 Phase 4 Topical travoprost;Tobramycin;Dexamethasone
19 Cefazolin-Lidocaine Solution for Reducing Pain Associated With Subconjunctival Antibiotic Prophylaxis in Vitreo-Retinal Surgery Unknown status NCT02324166 Phase 4 Cefazolin;Lidocaine
20 Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation Unknown status NCT01729494 Phase 4 Alemtuzumab;rabbit antithymocyte globulin;Belatacept;Tacrolimus;Mycophenolate mofetil;early cessation of steroids
21 Pilot Study of Prevention Myopia in Children With Low Concentration of Atropine Unknown status NCT00541177 Phase 4 atropine;tropicamide
22 EFFECTS OF IMMEDIATE ARGON LASER PERIPHERAL IRIDOPLASTY Versus CONVENTIONAL SYSTEMIC MEDICAL THERAPY ON OPTIC NERVE HEAD STRUCTURE AND FUNCTION OF ACUTE PRIMARY ANGLE CLOSURE EYES Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
23 A Phase IV, Multicenter, Randomized, Active Comparator Controlled Study of the Addition of Pioglitazone Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Alogliptin Unknown status NCT02426294 Phase 4 Pioglitazone;Glimepiride
24 Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery Completed NCT01383057 Phase 4
25 Laser Cataract Surgery With the Femtosecond Laser Technology Completed NCT01382823 Phase 4
26 Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric Intraocular Lens (IOL): Postmarket Evaluation Completed NCT00818116 Phase 4
27 Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions Completed NCT01298973 Phase 4 Viscoat;Saline
28 Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial Completed NCT01279031 Phase 4
29 Selection of Aspheric Diffractive Multifocal IOLS Based on Corneal Wavefront Completed NCT00999492 Phase 4
30 Evaluation of the Acrysof Toric Model SN60T3 Intraocular Lens in Patients With Predicted Residual Corneal Astigmatism Between 0.75 and 1.03 Diopters (D) Completed NCT00732030 Phase 4
31 Clinical Outcomes With AcrySof ReSTOR Aspheric Apodized Diffractive Intraocular Lens (IOL) in One Eye and a Contralateral Monofocal IOL or Phakic Eye Completed NCT00731640 Phase 4
32 A Prospective, Randomized Single-Masked Clinical Trial Comparing OCT and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care Completed NCT00698724 Phase 4 Xibrom, and Optive;Xibrom and Pred Forte
33 Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery Completed NCT00758199 Phase 4 Bromfenac;Moxifloxacin hydrochloride;Prednisolone Acetate
34 A Randomized, Masked Multi-center Safety & Efficacy Study of the Effects of Preoperative & Postoperative Cataract Surgery Use of Difluprednate Ophthalmic Emulsion, 0.05% Compared to Prednisolone Acetate Ophthalmic Suspension 1% on Visual Acuity & Corneal Edema. Completed NCT01244334 Phase 4 Difluprednate ophthalmic emulsion 0.05%;Prednisolone acetate 1%
35 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification Completed NCT01296191 Phase 4 Moxifloxacin;besifloxacin
36 A Comparison of Peak Aqueous Penetration of Acuvail, Xibrom, and Nevanac in Patients Undergoing Phacoemulsification Completed NCT01001806 Phase 4 Ketorolac Tromethamine 0.45%;bromfenac 0.09%;nepafenac 0.1%
37 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail, Xibrom and Nevanac in Patients Undergoing Phacoemulsification Completed NCT01021761 Phase 4 Ketorolac Tromethamine;Bromfenac;nepafenac
38 Effect of Nepafenac on Post-operative Cystoid Macular Edema Following Uncomplicated Cataract Surgery Completed NCT00494494 Phase 4 Standard Care;nepafenac
39 Clinical Outcomes After Bilateral Implantation of ZEISS AT LISA TRI AND TRI TORIC IOL Completed NCT02770924 Phase 4
40 A Randomised Trial of Torsional Ultrasound Versus Longitudinal Ultrasound During Phacoemulsification of Age-related Cataracts: Comparison of Intra-operative Performance and Impact on Post-operative Endothelium Integrity Completed NCT01010490 Phase 4
41 Comparison of the Quality of Vision Provided by AMO Tecnis Z9000 Three-piece Silicone Posterior Chamber Intraocular Lens and Alcon Laboratories MA60 Acrysof Three-piece Acrylic Posterior Chamber Intraocular Lens Completed NCT00348270 Phase 4
42 Indomethacin Eyedrops Compared With Ketorolac Eyedrops for Ocular Inflammation Following Cataract Surgery Completed NCT00904904 Phase 4 Indomethacin ophthalmic solution;Ketorolac Ophthalmic Solution
43 Monocular Study to Evaluate the Safety and Effectiveness of the Akreos™ Toric IOL When Used to Correct Primary Aphakia With the Reduction of Astigmatism Completed NCT00825513 Phase 4
44 Parallel-group Study of Ocular Penetration of Peri-operative Topically Administered Fluoroquinolones With Cataract Surgery Completed NCT00924729 Phase 4 Moxifloxacin 0.5% ophthalmic solution;Besifloxacin 0.6% ophthalmic suspension
45 Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients Completed NCT01859702 Phase 4 Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution
46 Therapeutic Variables in Cataract Surgery Completed NCT00407017 Phase 4 Gatifloxacin;Ketorolac LS;Pred Forte;Moxifloxacin;Nepafenac;EconoPred Plus
47 Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery Completed NCT00348582 Phase 4 Ketorolac, Nepafenac
48 A Masked Comparison of Acular LS Plus Steroid Versus Steroid Alone for the Prevention of Macular Leakage in Cataract Patients Completed NCT00348244 Phase 4 Ketorolac, Prednisolone Acetate
49 DisCoVisc Versus Competitor Completed NCT00712244 Phase 4
50 Use of Toric Intraocular Lens to Neutralize Keratometric Astigmatism Completed NCT00925886 Phase 4

Search NIH Clinical Center for Cataract

Genetic Tests for Cataract

Genetic tests related to Cataract:

# Genetic test Affiliating Genes
1 Cataract (disease) 29

Anatomical Context for Cataract

MalaCards organs/tissues related to Cataract:

40
Eye, Endothelial, Testes, Bone, Bone Marrow, Retina, Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cataract:
# Tissue Anatomical CompartmentCell Relevance
1 Eye Lens Affected by disease

Publications for Cataract

Articles related to Cataract:

(show top 50) (show all 38093)
# Title Authors PMID Year
1
Femtosecond laser-assisted versus phacoemulsification cataract surgery (FEMCAT): a multicentre participant-masked randomised superiority and cost-effectiveness trial. 42 61
31954466 2020
2
Review of anaesthetic management for cataract surgery in transplant recipients. 61 42
31914784 2020
3
Effects of capsular tension ring on surgical outcomes of premium intraocular lens in patients with suspected zonular weakness. 42
32092103 2020
4
Cerebrotendinous xanthomatosis (CTX): an association of pulverulent cataracts and pseudo-dominant developmental delay in a family with a splice site mutation in CYP27A1--a case report. 61 54
20450308 2010
5
In vivo lens deficiency of the R49C alphaA-crystallin mutant. 61 54
20188090 2010
6
A novel human CRYGD mutation in a juvenile autosomal dominant cataract. 54 61
20508808 2010
7
Oxidative stress markers in patients with primary open-angle glaucoma. 61 54
20373896 2010
8
Hyperferritinaemia-cataract syndrome: worldwide mutations and phenotype of an increasingly diagnosed genetic disorder. 61 54
20511138 2010
9
HTS-Compatible Patient-Derived Cell-Based Assay to Identify Small Molecule Modulators of Aberrant Splicing in Myotonic Dystrophy Type 1. 61 54
20502647 2010
10
A novel mutation in the major intrinsic protein (MIP) associated with autosomal dominant congenital cataracts in a Chinese family. 54 61
20361015 2010
11
Later retinal degeneration following childhood surgical aphakia in a family with recessive CRYAB mutation (p.R56W). 54 61
20141356 2010
12
[Progress in pathogenic genes and their functions of congenital cataract]. 54 61
20450675 2010
13
A novel GJA8 mutation (p.I31T) causing autosomal dominant congenital cataract in a Chinese family. 61 54
20019893 2009
14
Megakaryocyte and platelet abnormalities in a patient with a W33C mutation in the conserved SH3-like domain of myosin heavy chain IIA. 54 61
19967157 2009
15
[Hereditary hyperferritinemia cataract syndrome--the first family in Germany]. 61 54
19994473 2009
16
Glucose-6-phosphate dehydrogenase (G6PD) deficiency and senile cataract in a Sardinian male population, Italy. 54 61
19995205 2009
17
Synergistic effects of metal ion and the pre-senile cataract-causing G98R alphaA-crystallin: self-aggregation propensities and chaperone activity. 54 61
19862354 2009
18
[Mutation analysis of the PAX6 gene in a family with congenital aniridia and cataract]. 61 54
19806578 2009
19
A novel mutation (F71L) in alphaA-crystallin with defective chaperone-like function associated with age-related cataract. 54 61
19595763 2009
20
Mutations in MYH9 exons 1, 16, 26, and 30 are infrequently found in Japanese patients with nonsyndromic deafness. 61 54
19645626 2009
21
Effects of alpha-crystallin on lens cell function and cataract pathology. 54 61
19860667 2009
22
A novel gammaD-crystallin mutation causes mild changes in protein properties but leads to congenital coralliform cataract. 61 54
19668596 2009
23
Age-related cataracts and Prdx6: correlation between severity of lens opacity, age and the level of Prdx 6 expression. 54 61
19429582 2009
24
Antioxidant status modifications by topical administration of dorzolamide in primary open-angle glaucoma. 54 61
19551670 2009
25
Founder heterozygous P23T CRYGD mutation associated with cerulean (and coralliform) cataract in 2 Saudi families. 61 54
19633732 2009
26
EPHA2 is associated with age-related cortical cataract in mice and humans. 54 61
19649315 2009
27
Aquaporins: translating bench research to human disease. 61 54
19448080 2009
28
An alphaA-crystallin gene mutation, Arg12Cys, causing inherited cataract-microcornea exhibits an altered heat-shock response. 54 61
19503744 2009
29
Bilateral cataract in a subject carrying a C to A transition in the L ferritin promoter region. 54 61
19254706 2009
30
Topical use of coenzyme Q10-loaded liposomes coated with trimethyl chitosan: tolerance, precorneal retention and anti-cataract effect. 61 54
19437594 2009
31
Deletion of mouse MsrA results in HBO-induced cataract: MsrA repairs mitochondrial cytochrome c. 61 54
19461988 2009
32
Identification of a novel CRYAB mutation associated with autosomal recessive juvenile cataract in a Saudi family. 54 61
19461931 2009
33
Initiation codon mutation in betaB1-crystallin (CRYBB1) associated with autosomal recessive nuclear pulverulent cataract. 61 54
19461930 2009
34
Aquaporin water channels in mammals. 61 54
19085041 2009
35
NMR study of the cataract-linked P23T mutant of human gammaD-crystallin shows minor changes in hydrophobic patches that reflect its retrograde solubility. 61 54
19275895 2009
36
Removal of Hsf4 leads to cataract development in mice through down-regulation of gamma S-crystallin and Bfsp expression. 54 61
19224648 2009
37
11p Microdeletion including WT1 but not PAX6, presenting with cataract, mental retardation, genital abnormalities and seizures: a case report. 54 61
19222835 2009
38
Mitochondrial function and redox control in the aging eye: role of MsrA and other repair systems in cataract and macular degenerations. 54 61
18588875 2009
39
Genetics of crystallins: cataract and beyond. 61 54
19007775 2009
40
Autosomal-dominant cerulean cataract in a chinese family associated with gene conversion mutation in beta-B2-crystallin. 61 54
19321936 2009
41
A new locus for congenital cataract, microcornea, microphthalmia, and atypical iris coloboma maps to chromosome 2. 54 61
19004499 2009
42
Novel mutation in the gamma-S crystallin gene causing autosomal dominant cataract. 61 54
19262743 2009
43
Structural function of MIP/aquaporin 0 in the eye lens; genetic defects lead to congenital inherited cataracts. 54 61
19096783 2009
44
Oxidative stress markers in aqueous humor of patients with senile cataracts. 61 54
19172468 2009
45
Disulfide cross-links in the interaction of a cataract-linked alphaA-crystallin mutant with betaB1-crystallin. 54 61
19071118 2009
46
N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population. 61 54
19503764 2009
47
Synergistic effect of osmotic and oxidative stress in slow-developing cataract formation. 54 61
18760274 2008
48
A missense mutation in ALDH18A1, encoding Delta1-pyrroline-5-carboxylate synthase (P5CS), causes an autosomal recessive neurocutaneous syndrome. 61 54
18478038 2008
49
Genistein inhibits aldose reductase activity and high glucose-induced TGF-beta2 expression in human lens epithelial cells. 54 61
18692043 2008
50
Mechanism of insolubilization by a single-point mutation in alphaA-crystallin linked with hereditary human cataracts. 54 61
18700785 2008

Variations for Cataract

ClinVar genetic disease variations for Cataract:

6 (show top 50) (show all 93) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 LIM2 NM_001161748.2(LIM2):c.388C>T (p.Arg130Cys)SNV Pathogenic 625113 rs1568480054 19:51883831-51883831 19:51380577-51380577
2 SIL1 NC_000005.10:g.139189727_139201554deldeletion Pathogenic 812923 5:138525416-138537243
3 RHO NM_000539.3(RHO):c.891C>G (p.Ser297Arg)SNV Pathogenic 523376 rs142285818 3:129251570-129251570 3:129532727-129532727
4 IARS2 NM_018060.4(IARS2):c.2726C>T (p.Pro909Leu)SNV Pathogenic 156553 rs587783070 1:220316451-220316451 1:220143109-220143109
5 46;XY;inv(9)(q22.3q34.11)dninversion Pathogenic 267868
6 WRN NM_000553.6(WRN):c.724+1G>TSNV Likely pathogenic 523380 rs1339616347 8:30925844-30925844 8:31068328-31068328
7 COL5A1 NM_001278074.1(COL5A1):c.608G>T (p.Gly203Val)SNV Likely pathogenic 523328 rs1554781700 9:137593133-137593133 9:134701287-134701287
8 COL18A1 NM_030582.4(COL18A1):c.1469-2A>GSNV Likely pathogenic 373962 rs765919785 21:46897323-46897323 21:45477409-45477409
9 COL18A1 NM_030582.4(COL18A1):c.3979C>T (p.Arg1327Ter)SNV Likely pathogenic 373961 rs1057518802 21:46929468-46929468 21:45509554-45509554
10 PITX2 NM_153427.2(PITX2):c.-1385+12T>CSNV Conflicting interpretations of pathogenicity 901581 4:111563063-111563063 4:110641907-110641907
11 PITX2 NM_153427.2(PITX2):c.-79G>ASNV Conflicting interpretations of pathogenicity 900591 4:111558005-111558005 4:110636849-110636849
12 PITX2 NM_153427.2(PITX2):c.-211G>ASNV Conflicting interpretations of pathogenicity 902274 4:111558137-111558137 4:110636981-110636981
13 PITX2 NM_000325.6(PITX2):c.619A>G (p.Met207Val)SNV Conflicting interpretations of pathogenicity 559593 rs138163892 4:111539637-111539637 4:110618481-110618481
14 PITX2 NM_153427.2(PITX2):c.-793C>ASNV Conflicting interpretations of pathogenicity 902484 4:111558719-111558719 4:110637563-110637563
15 PITX2 NM_153427.2(PITX2):c.-967C>TSNV Conflicting interpretations of pathogenicity 900892 4:111558893-111558893 4:110637737-110637737
16 PITX2 NM_000325.6(PITX2):c.639A>T (p.Ser213=)SNV Conflicting interpretations of pathogenicity 283383 rs141176394 4:111539617-111539617 4:110618461-110618461
17 EPM2A NM_005670.4(EPM2A):c.376A>G (p.Ile126Val)SNV Conflicting interpretations of pathogenicity 167038 rs150452237 6:146007358-146007358 6:145686222-145686222
18 PITX2 NM_153427.2(PITX2):c.-1532C>ASNV Conflicting interpretations of pathogenicity 901637 4:111563222-111563222 4:110642066-110642066
19 PITX2 NM_000325.6(PITX2):c.*340A>GSNV Conflicting interpretations of pathogenicity 347294 rs551209662 4:111538941-111538941 4:110617785-110617785
20 PITX2 NM_000325.6(PITX2):c.862C>T (p.Leu288=)SNV Conflicting interpretations of pathogenicity 347298 rs139401187 4:111539394-111539394 4:110618238-110618238
21 PITX2 NM_000325.6(PITX2):c.224A>C (p.Gln75Pro)SNV Conflicting interpretations of pathogenicity 347300 rs201628949 4:111542507-111542507 4:110621351-110621351
22 MIP NM_012064.4(MIP):c.*1777dupduplication Uncertain significance 309861 rs886049688 12:56843286-56843287 12:56449502-56449503
23 PITX2 NM_000325.6(PITX2):c.*176A>TSNV Uncertain significance 347296 rs567517676 4:111539105-111539105 4:110617949-110617949
24 PITX2 NM_000325.6(PITX2):c.*119T>ASNV Uncertain significance 347297 rs765040142 4:111539162-111539162 4:110618006-110618006
25 MIP NM_012064.4(MIP):c.*1237_*1238dupduplication Uncertain significance 309864 rs111463603 12:56843825-56843826 12:56450041-56450042
26 PITX2 NM_000325.6(PITX2):c.*370G>CSNV Uncertain significance 347293 rs886059005 4:111538911-111538911 4:110617755-110617755
27 PITX2 NM_000325.6(PITX2):c.*264A>CSNV Uncertain significance 347295 rs886059006 4:111539017-111539017 4:110617861-110617861
28 PITX2 NM_000325.6(PITX2):c.412-11deldeletion Uncertain significance 347299 rs886059007 4:111539855-111539855 4:110618699-110618699
29 PITX2 NM_000325.6(PITX2):c.*611A>GSNV Uncertain significance 347288 rs886059002 4:111538670-111538670 4:110617514-110617514
30 PITX2 NM_000325.6(PITX2):c.*522T>CSNV Uncertain significance 347290 rs188349821 4:111538759-111538759 4:110617603-110617603
31 PITX2 NM_000325.6(PITX2):c.*572T>CSNV Uncertain significance 347289 rs886059003 4:111538709-111538709 4:110617553-110617553
32 PITX2 NM_000325.6(PITX2):c.*373_*375GTT[1]short repeat Uncertain significance 347292 rs886059004 4:111538903-111538905 4:110617747-110617749
33 PITX2 NM_000325.6(PITX2):c.412-7C>TSNV Uncertain significance 899414 4:111539851-111539851 4:110618695-110618695
34 PITX2 NM_153427.2(PITX2):c.-1078C>ASNV Uncertain significance 899796 4:111559004-111559004 4:110637848-110637848
35 PITX2 NM_153427.2(PITX2):c.-1092G>ASNV Uncertain significance 899797 4:111559018-111559018 4:110637862-110637862
36 PITX2 NM_153427.2(PITX2):c.-1411C>TSNV Uncertain significance 901582 4:111563101-111563101 4:110641945-110641945
37 PITX2 NM_153427.2(PITX2):c.-1421G>CSNV Uncertain significance 899913 4:111563111-111563111 4:110641955-110641955
38 PITX2 NM_153427.2(PITX2):c.-1422C>ASNV Uncertain significance 899914 4:111563112-111563112 4:110641956-110641956
39 PITX2 NM_153427.2(PITX2):c.-1491G>ASNV Uncertain significance 901089 4:111563181-111563181 4:110642025-110642025
40 UPF3B NM_080632.2(UPF3B):c.758T>C (p.Ile253Thr)SNV Uncertain significance 284394 rs754982440 X:118975088-118975088 X:119841125-119841125
41 CRYGD NM_006891.3(CRYGD):c.-80A>CSNV Uncertain significance 333880 rs886055528 2:208989277-208989277 2:208124553-208124553
42 XDH NM_000379.4(XDH):c.3647C>A (p.Pro1216His)SNV Uncertain significance 335760 rs143981573 2:31562482-31562482 2:31339616-31339616
43 PITX2 NM_153427.2(PITX2):c.-920C>TSNV Uncertain significance 899730 4:111558846-111558846 4:110637690-110637690
44 PITX2 NM_153427.2(PITX2):c.-966A>GSNV Uncertain significance 899731 4:111558892-111558892 4:110637736-110637736
45 PITX2 NM_153427.2(PITX2):c.-1137G>ASNV Uncertain significance 902615 4:111559063-111559063 4:110637907-110637907
46 PITX2 NM_153427.2(PITX2):c.-1209C>TSNV Uncertain significance 899850 4:111559135-111559135 4:110637979-110637979
47 XDH NM_000379.4(XDH):c.1172C>T (p.Pro391Leu)SNV Uncertain significance 598996 rs1558697792 2:31602803-31602803 2:31379937-31379937
48 PITX2 NM_153427.2(PITX2):c.-501T>GSNV Uncertain significance 899665 4:111558427-111558427 4:110637271-110637271
49 PITX2 NM_153427.2(PITX2):c.-515C>TSNV Uncertain significance 899666 4:111558441-111558441 4:110637285-110637285
50 PITX2 NM_153427.2(PITX2):c.-670C>TSNV Uncertain significance 900813 4:111558596-111558596 4:110637440-110637440

Copy number variations for Cataract from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 86882 14 67000000 106368585 Copy number cataract
2 89231 15 17000000 100338915 Copy number cataract
3 106728 17 1 11200000 Copy number cataract

Expression for Cataract

Search GEO for disease gene expression data for Cataract.

Pathways for Cataract

Pathways related to Cataract according to KEGG:

36
# Name Kegg Source Accession
1 Protein processing in endoplasmic reticulum hsa04141

GO Terms for Cataract

Cellular components related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gap junction GO:0005921 8.96 GJA8 GJA3
2 connexin complex GO:0005922 8.62 GJA8 GJA3

Biological processes related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.5 RHO GJA3 CRYGS CRYGD CRYBB3 CRYBA1
2 gap junction-mediated intercellular transport GO:1990349 9.16 GJA8 GJA3
3 lens development in camera-type eye GO:0002088 9.1 LIM2 GJA8 CRYGS CRYGD CRYBB3 CRYBA1

Molecular functions related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of eye lens GO:0005212 9.1 LIM2 CRYGS CRYGD CRYBB3 CRYBA1 CRYAA
2 gap junction channel activity GO:0005243 8.96 GJA8 GJA3

Sources for Cataract

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....